tetano
Editor, Senior Moderator
Vaxart, Inc., a privately held, clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced enrollment of the first patient in a Phase 1 human clinical trial to evaluate Vaxart?s influenza B tablet vaccine.
The influenza B Phase 1 trial is a randomized, double-blind, placebo-controlled study.
Recently The Lancet Infectious Diseases published findings from a recent influenza A Phase 1 trial demonstrating that Vaxart?s influenza A tablet vaccine generated both neutralizing antibodies as well as a robust mucosal immune response in 92 percent of subjects after a single dose.
http://finance.yahoo.com/news/vaxart-announces-enrollment-first-patient-130000312.html
The influenza B Phase 1 trial is a randomized, double-blind, placebo-controlled study.
Recently The Lancet Infectious Diseases published findings from a recent influenza A Phase 1 trial demonstrating that Vaxart?s influenza A tablet vaccine generated both neutralizing antibodies as well as a robust mucosal immune response in 92 percent of subjects after a single dose.
http://finance.yahoo.com/news/vaxart-announces-enrollment-first-patient-130000312.html